<DOC>
	<DOCNO>NCT00006038</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy drug different way may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow surgery intraperitoneal chemotherapy treat patient locally advanced stomach cancer .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Surgery Intraperitoneal Chemotherapy Treating Patients With Locally Advanced Stomach Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine efficacy toxicity neoadjuvant cisplatin , fluorouracil , docetaxel , postoperative intraperitoneal floxuridine leucovorin calcium patient locally advance adenocarcinoma stomach gastroesophageal junction . II . Determine whether molecular marker , include thymidylate synthase , excision repair cross complement gene , tubulin isoform 4B , sensitivity fluorouracil , cisplatin , docetaxel , respectively , predictive outcome ( disease free survival overall survival ) patient . III . Determine quality life patient treat regimen . OUTLINE : During week 1 4 , patient receive docetaxel IV 1 hour follow cisplatin IV 30-60 minute day 1 , fluorouracil IV continuously day 1-5 . During week 6-8 , patient undergo radical subtotal total gastrectomy D2 lymph node dissection follow percutaneous placement intraperitoneal port device . Beginning within 5 day resection , patient clear margin receive floxuridine leucovorin calcium intraperitoneally day 1-3 week 1 , 3 , 5 absence disease progression unacceptable toxicity . Quality life assess prior begin study , prior surgery , monthly 3 month begin completion study therapy , every 3 month year 2 , every 6 month year 3 . Patients follow monthly 3 month , every 3 month year 2 , every 6 month though year 3 . PROJECTED ACCRUAL : A total 50 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove locally advanced adenocarcinoma stomach gastroesophageal ( GE ) junction potentially curable surgery Patients tumor involve GE junction must bulk disease stomach No tumor distal esophagus GE junction extend le 2 cm stomach Tumor stage T2 , N12 , M0 OR T34 , N , M0 physical exam , CT scan , laparoscopy PATIENT CHARACTERISTICS : Age : Any age Performance status : Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : WBC least 4,000/mm3 Platelet count least 150,000/mm3 Hepatic : Bilirubin le 2 mg/dL SGOT and/or SGPT great 2.5 time upper limit normal ( ULN ) alkaline phosphatase great ULN OR Alkaline phosphatase great 4 time ULN SGOT and/or SGPT great ULN Ineligible SGOT SGPT great 1.5 time ULN AND alkaline phosphatase great 2.5 time ULN Renal : Blood urea nitrogen great 30 mg/dL Creatinine great 1.5 mg/dL AND/OR Creatinine clearance great 50 mL/min Cardiovascular : No New York Heart Association class III IV heart disease No active angina myocardial infarction within past 6 month No history significant ventricular arrhythmia require medication antiarrhythmic significant conduction system abnormality Other : No clinically significant auditory impairment No bad grade 2 preexist peripheral neuropathy No malignancy within past 5 year except nonmelanomatous skin cancer carcinoma situ cervix Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No serious concurrent infection nonmalignant illness uncontrolled whose control may jeopardize complication study therapy No psychiatric disorder would preclude compliance PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>